Results 201 to 210 of about 2,536,282 (288)
Roadmap of Anaphylaxis Registries Across the World
Clinical &Experimental Allergy, EarlyView.
Guillaume Pouessel+8 more
wiley +1 more source
Abstract Background The incidence of and risk factors for infusion‐related reactions to intravenous iron formulations remains poorly characterised. This study aimed to compare the rates of infusion reactions in patients receiving ferric derisomaltose (FDI) compared to ferric carboxymaltose (FCM), as well as across different dilutions of FDI.
Sarah Lucas+9 more
wiley +1 more source
<i>Scutellaria baicalensis</i> extracts alleviate zymosan-induced irritable bowel syndrome symptoms by modulating inflammation and ion channel activity. [PDF]
Choi NR+5 more
europepmc +1 more source
ABSTRACT Aim This study aimed to examine the physical symptoms, coping strategies for earthquake stress and factors predicting coping strategies among adults staying in tent cities after an earthquake. Design A cross‐sectional design was conducted. Methods The study sample consisted of 706 adults residing in tent cities in three cities of earthquake ...
Ayşegül Akca+4 more
wiley +1 more source
From burden to breakthrough: Advances in hereditary angioedema, drug allergy, and allergic disease prevention. [PDF]
Bellanti JA, Settipane RA.
europepmc +1 more source
The frequency and severity of hypoglycemia peak before lunch and its nadir is 17:30 PM and increases through the post‐discharge days. ABSTRACT Introduction Insulin improves clinical outcomes in hospitalized patients; however, hypoglycemia hinders discharge transition in patients with insulin‐treated diabetes.
Manabu Saito+5 more
wiley +1 more source
Hypersensitivity Reaction After Administration of Crotalidae Polyvalent Immune Fab (CroFab). [PDF]
Truong L, Anis TR, Najibfard L, Peck E.
europepmc +1 more source
European Guideline (EuroGuiDerm) on atopic eczema: Living update
The updated guideline includes a new evidence‐based recommendation for the IL‐13 inhibitor lebrikizumab. In addition, the Janus kinase inhibitors baricitinib and abrocitinib, which were initially only approved for adult patients, are now also recommended for children from the age of 2 and adolescents from the age of 12, respectively.
A. Wollenberg+31 more
wiley +1 more source
Latex allergy: a challenge for anaesthetists [PDF]
Demaegd, J, Herregods, Luc, Soetens, F
core +1 more source
Food hypersensitivity in patients suffering from atopic dermatitis and sensitization to soy.
Celakovská J+5 more
europepmc +1 more source